by
Brendon Nafziger, DOTmed News Associate Editor | January 10, 2011
Hologic Inc. said Friday it bought Interlace Medical Inc., a manufacturer of a device for removing uterine fibroids, for $125 million in cash.
The deal also includes two annual cash-contingent payments, based on revenue growth from the prior year.
"The acquisition of Interlace is consistent with our strategy to strengthen our leadership position in women's health care," Steve Williamson, Hologic's senior vice president and general manager of OB/GYN surgical products said in a statement.
Privately held Interlace, headquartered in Framingham, Mass., makes MyoSure, a minimally invasive system that removes fibroids and polyps. Nearly 5 million women in the United States suffer from fibroids or polyps that can be treated with the system, Hologic said.
Bedford, Mass.-based Hologic said it's rolling out doctor training and education programs and plans on fully promoting the product early this year.
